- Artis BioSolutions is advancing the development and manufacturing of next-generation therapies, with a focus on enabling complex modalities across the biopharma landscape.
- Through the acquisition of Landmark Bio, Artis is broadening its GMP capabilities to support a diverse pipeline of therapeutic programs with flexible, phase-appropriate development models.
- Artis is investing in infrastructure, talent, and strategic partnerships to accelerate innovation across nucleic acids, complex biologics, and other emerging therapeutic platforms.
- Artis partners closely with innovators to align technical execution with program objectives, ensuring quality, speed, and scalability from early development through clinical readiness.